Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients.
Mol Genet Metab Rep
; 30: 100843, 2022 Mar.
Article
de En
| MEDLINE
| ID: mdl-35242574
Biomarker; CLN2, neuronal ceroid lipofuscinosis type 2; CNS, central nervous system; CSF, cerebrospinal fluid; EDTA, Ethylenediaminetetraacetic acid; GBA2, non-lysosomal glucocerebrosidase; GCS, glucosylceramide synthase; GD3, Gaucher disease type 3; GFAP, Glial fibrillary acidic protein; Gangliosidosis; GlcSph, glucosylsphingosine; LC-MS/MS, liquid chromatography coupled with tandem mass spectrometry; LLOQ, lower limit of quantification; LSD, lysosomal storage disorders; Lysosome; Lysosphingolipid; MRI, magnetic resonance imaging; MS, multiple sclerosis; NF-L, Neurofilament light chain; NPC, Niemann Pick disease type C; Neurofilament; QC, quality control; lysoGb3, globotriaosylsphingosine
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Langue:
En
Journal:
Mol Genet Metab Rep
Année:
2022
Type de document:
Article
Pays d'affiliation:
Suisse
Pays de publication:
États-Unis d'Amérique